Table 2. Comparison of demographic, clinical, and laboratory findings in patients with and without restless leg syndrome.
* p-values showing statistically significant results.
Continuous data are presented as mean ± standard deviation or median (IQR).
AZA: azathioprine, BMI: body mass index, BVAS: Birmingham vasculitis activity score, CS: corticosteroid, CYC: cyclophosphamide, EGPA: eosinophilic granulomatous polyangiitis, GPA: granulomatous polyangiitis, MCS: mental component summary, MMF: mycophenolate mofetil, MPA: microscopic polyangiitis, MTX: methotrexate, PCS: physical component summary, RTX: rituximab, RLS: restless leg syndrome, SF-36: Short Form-36, UIBC: unsaturated iron-binding capacity
| Variables | Without RLS (n=25) | With RLS (n=5) | p-value |
| Age, years | 52.8±13.8 | 46.6±14.6 | 0.803 |
| Male gender, n (%) | 13 (52) | 5 (100) | 0.049* |
| BMI, kg/m2 | 26.6±4.6 | 28.3±0.9 | 0.419 |
| Disease duration, months | 77.6±38.2 | 70.0±35.0 | 0.685 |
| Diseases, n (%) | |||
| GPA | 15 (60) | 4 (80) | 0.420 |
| MPA | 6 (24) | 1 (20) | - |
| EGPA | 4 (16) | 0 (0) | - |
| Comorbidities, n (%) | |||
| Hypertension | 12 (48) | 1 (20) | 0.355 |
| Diabetes mellitus | 6 (24) | 1 (20) | 0.671 |
| Chronic respiratory diseases | 9 (36) | 0 (0) | 0.286 |
| Chronic kidney disease | 6 (24) | 0 (0) | 0.553 |
| Osteoporosis | 9 (36) | 1 (20) | 0.640 |
| Coronary artery disease | 2 (8) | 0 (0) | 0.690 |
| Treatment ever used, n (%) | |||
| MTX | 4 (16) | 1 (20) | 0.627 |
| AZA | 5 (20) | 1 (20) | 0.702 |
| MMF | 2 (8) | 0 (0) | 0.690 |
| CYC | 20 (80) | 4 (80) | 1.000 |
| RTX | 15 (60) | 3 (60) | 1.000 |
| CS | 25 (100) | 5 (100) | 1.000 |
| Disease activity at the time of evaluation, n (%) | |||
| Active disease | 9 (36) | 0 (0) | 0.286 |
| Remission | 16 (64) | 5 (100) | |
| BVAS | 3 (7) | 0 (5) | 0.208 |
| Presence of persistent organ damage, n (%) | 17 (2) | 2 (40) | 0.327 |
| Hemoglobin, g/dL | 13.6±2.5 | 15.1±1.4 | 0.213 |
| Vitamine D, ng/mL | 20 (16.7) | 21 (9.5) | 0.817 |
| Vitamine B12, pg/mL | 416.4 (169.2) | 349 (973) | 0.872 |
| Folic acid, ng/mL | 8.1±3.6 | 6.2±3.1 | 0.275 |
| Iron, µg/dL | 76±44.6 | 48.6±36.8 | 0.209 |
| UIBC, µg/dL | 244.6±68.2 | 211.4±71.0 | 0.331 |
| Neuropathic pain, n (%) | 6 (33.3) | 2(11.1) | 0.178 |
| SF-36 questionnaire | |||
| Physical functioning | 90 (37.5) | 85 (20) | 0.787 |
| Role limitations due to physical health | 100 (100) | 75 (75) | 0.829 |
| Role limitations due to emotional problems | 50 (57.5) | 100 (83.5) | 0.229 |
| Energy fatigue | 53.4±19.5 | 53.0±30.1 | 0.970 |
| Emotional well-being | 72 (32) | 68 (56) | 0.872 |
| Social functioning | 75 (48.8) | 75 (62.5) | 0.914 |
| Pain | 77.5 (48.8) | 77.5 (55) | 0.829 |
| General health | 50.0±16.2 | 53.0±21.7 | 0.723 |
| Health change | 50 (25) | 50 (50) | 0.872 |
| SF-36-PCS | 75.6 (39.2) | 65 (44.4) | 0.829 |
| SF-36-MCS | 65.9±20.7 | 69.1±18.1 | 0.721 |